摘要
目的探讨莫西沙星对急性肺脓肿治疗的临床疗效及安全性分析。方法选择2008年6月-2009年6月收治的36例急性肺脓肿患者,随机分为莫西沙星组和对照组,分别给予静脉滴注莫西沙星和头孢哌酮舒巴坦联合替硝唑治疗。比较两组疗效及安全性。结果莫西沙星组和对照组总有效率分别为90.63%、93.75%;细菌敏感性分别为73.3%、86.7%;细菌清除率分别为83.7%、92.4%;不良反应总发生率分别为16.7%、11.1%。两组比较无统计学差异(P>0.05)。结论经验性莫西沙星治疗急性肺脓肿的疗效及安全性与头孢哌酮舒巴坦联合替硝唑相似。但莫西沙星治疗费用低且利于口服序贯治疗而更具有优势,可推荐作为经验性或首选用药。
Objective To evaluate the clinical efficacy and security of moxifloxac in treating patients with acute lung abscess. Methods Thirty-six patients sufferring from acute lung abscess of admission were divided into two groups randomly from June 2008 to June 2009. The patients in treatment group were given moxifloxacin by intravenous way, and the patients in control group were given cefoperazone and sulbactam combination with tinidazole. Clinical efficacy and security were observed and compared respectively. Results The total effective rate in treatment group and control group was 90.63% and 93.75% respectively; the sensitive rate of the two groups was 73.3% and 86.7% respectively; the clearance rate of bacteria was 83.7% and 92.4% respectively. The overall incidence of adverse reactions was 16.7% in treatment group and 11.1% in control group. No statistical difference was found between the two groups (P>0.05). Conclusion In the empirical teatment of acute lung abscess, the clinical efficacy and security of moxifloxacin are almost the same as the combination of cefoperazone and sulbactam and tinidazole. Moxifloxacin can be recommended as empirical or preferred choice due to its lower cost and convenience to oral sequential treatment.
出处
《华西医学》
CAS
2010年第3期468-470,共3页
West China Medical Journal
关键词
莫西沙星
急性肺脓肿
临床疗效
安全性
Moxifloxacin
Acute lung abscess
Clinical efficacy
Security
